Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC)
therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination
with LDAC will be identified, and that the combination therapy will show evidence of clinical
activity in adult patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and
Advanced Myelodysplastic Syndromes (MDS).